The plain radiographic features of gout are well known; however, the sensitivity
of plain radiographs alone for the detection of signs of gout is poor in acute
disease. Radiographic abnormalities do not manifest until late in the disease
process, after significant joint and soft tissue damage has already occurred.
The advent of dual-energy computed tomography (DECT) has enabled the
non-invasive diagnosis and quantification of gout by accurately confirming the
presence and extent of urate crystals in joints and soft tissues, without the
need for painful and often unreliable soft tissue biopsy or joint aspiration.
Specific ultrasound findings have been identified and may also be used to aid
diagnosis. Both ultrasound and magnetic resonance imaging (MRI) may be used for
the measurement of disease extent, monitoring of disease activity or treatment
response, although MRI findings are nonspecific. In this article we summarize
the imaging findings and diagnostic utility of plain radiographs, ultrasound,
DECT, MRI and nuclear medicine studies in the assessment as well as the
implications and utility these tools have for measuring disease burden and
therapeutic response.